Bioventus Postpones IPO

Bioventus is reported to have delayed its US $150MM initial public offering.

Bioventus formed in 2012 when Smith & Nephew spun out its biologics and clinical therapies division in a joint venture with Essex Woodlands, a venture capital firm.

Earlier this month, Bioventus entered into an agreement with Seikagaku to continue U.S....

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us